Get the Stockscreener App
0.2164
3.10%
0.0065
After Hours:
.21
-0.0064
-2.96%
Theriva Biologics Inc stock is traded at $0.2164, with a volume of 347.93K.
It is up +3.10% in the last 24 hours and down -3.86% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.2099
Open:
$0.2114
24h Volume:
347.93K
Relative Volume:
0.60
Market Cap:
$9.93M
Revenue:
$300.00K
Net Income/Loss:
$-21.46M
P/E Ratio:
-0.0855
EPS:
-2.5324
Net Cash Flow:
$-14.40M
1W Performance:
-4.71%
1M Performance:
-3.86%
6M Performance:
-15.17%
1Y Performance:
-74.24%
1-Day Range:
$0.2096
$0.221
1-Week Range:
$0.2096
$0.2362
52-Week Range:
$0.1628
$0.8632
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2164 | 9.93M | 300.00K | -21.46M | -14.40M | -2.5324 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Theriva Biologics Inc Stock (TOVX) Latest News
Form PRE 14A Theriva Biologics Inc For: 9 October By Investing.com - Investing.com Nigeria
Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico - GlobeNewswire Inc.
Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com - Investing.com Canada
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Yahoo! Finance Canada
Theriva™ Biologics Announces Publication of the Results - GlobeNewswire
Theriva Biologics Inc. (TOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Theriva Biologics Inc. (TOVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theriva Biologics Inc. (TOVX) Peer Comparison – Compare with Others - Value Research
Theriva Biologics Inc. (TOVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DayConsensus Beat Rate - vinanet.vn
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DaySaaS Earnings Trends - careplusvn.com
Theriva Biologics(TOVX) Stock Options Chain | Quotes & News - Moomoo
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportRounding Bottom - vinanet.vn
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportPCR Divergence - dars.gov.et
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportVolatility Skew - careplusvn.com
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportStock News - dars.gov.et
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneQuality Factor - vinanet.vn
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneUp Down Volume - https://www.siam.in/
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportSentiment Divergence - vinanet.vn
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportBuy Signal Reports - https://www.dars.gov.et/
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria
Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Canada
Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative
Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView
Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan
Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com
Theriva Biologics: Q2 Earnings Snapshot - AOL.com
Theriva Biologics: Q2 Earnings Snapshot - KTVB
Theriva Biologics 2Q Loss/Shr 7c >TOVX - Moomoo
BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics: Q2 Earnings Snapshot - finance.yahoo.com
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics Doses First Patients in VIRAGE2 Phase 2a Trial of Repeated VCN-01 Dosing in Metastatic Pancreatic Cancer - Quiver Quantitative
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - Yahoo Finance
Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa
Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com South Africa
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 - GlobeNewswire
Adding a virus to chemotherapy was linked to improved survival in a pancreatic cancer trial - Stock Titan
Theriva Biologics Expands Stock Incentive and Governance Plans - TipRanks
Theriva Biologics (NYSE American: TOVX) holders back bigger stock plan, warrants - Stock Titan
Theriva Biologics, Inc. Revenue Breakdown – AMEX:TOVX - TradingView
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):